Top Page
Ceribell, Inc.
(NASDAQ:CBLL)
Ceribell, Inc. (CBLL) vs. SPDR S&P 500 ETF (SPY)
Ceribell, Inc. Business Overview & Revenue Model
Ceribell, Inc. Earnings Call Summary
Ceribell, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 77.42M | 65.44M | 45.23M | 25.92M |
| Gross Profit | 67.94M | 56.75M | 38.16M | 21.49M |
| EBITDA | -46.17M | -37.71M | -26.51M | -35.06M |
| Net Income | -49.41M | -40.45M | -29.46M | -37.16M |
Balance Sheet | ||||
| Total Assets | 207.69M | 225.41M | 58.92M | 86.46M |
| Cash, Cash Equivalents and Short-Term Investments | 177.43M | 194.37M | 34.49M | 68.23M |
| Total Debt | 21.55M | 21.96M | 14.20M | 18.22M |
| Total Liabilities | 35.53M | 34.25M | 171.17M | 172.86M |
| Stockholders Equity | 172.16M | 191.16M | -112.25M | -86.40M |
Cash Flow | ||||
| Free Cash Flow | -38.60M | -36.38M | -30.14M | -32.52M |
| Operating Cash Flow | -37.45M | -35.04M | -29.16M | -32.00M |
| Investing Cash Flow | -137.61M | -1.60M | -1.76M | -1.40M |
| Financing Cash Flow | 190.85M | 196.52M | -2.82M | 49.80M |
Ceribell, Inc. Technical Analysis
Ceribell, Inc. Risk Analysis
Ceribell, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $343.87M | 216.04 | ― | ― | 251.26% | ― | |
| ― | $677.18M | ― | -29.42% | ― | 16.04% | 28.91% | |
| ― | $417.97M | ― | ― | ― | ― | ― | |
| ― | $485.13M | -3.61 | -25.57% | ― | -1.36% | -479.49% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $496.17M | ― | -1.67% | ― | -0.85% | 61.31% | |
| ― | $392.26M | ― | -15.36% | ― | -0.02% | -1196.44% |
Ceribell, Inc. Corporate Events
The Ceribell Delirium Data Collection Study aims to enhance the understanding and assessment of delirium subtypes by collecting clinical and rapid response EEG (rrEEG) data. This observational study, officially titled the ‘Ceribell Delirium Data Collection Study,’ is significant for its potential to develop software algorithms that could improve delirium diagnosis and treatment in clinical settings.
Ceribell, Inc. has been working with Shenzhen Everwin Precision Technology Co., Ltd. under a Corporate Supply Agreement initially established in January 2022. This agreement involves the supply of small and large headbands and grants Ceribell broad license rights to necessary product materials. The agreement has undergone several amendments, with the latest Amendment No. 3, dated September 22, 2025, designating Everwin Vietnam as an agent and providing for deliveries from Vietnam. These amendments extend the agreement’s term and expand the company’s operational capabilities, potentially enhancing its market positioning by diversifying its supply chain and production locations.
The most recent analyst rating on (CBLL) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
On September 17, 2025, Ceribell, Inc. appointed Erica Rogers to its Board of Directors, highlighting her extensive experience in leading high-growth medical device companies. Rogers’ appointment is seen as a strategic move to support Ceribell’s mission to expand nationwide access to its point-of-care EEG system, which has already improved care for critically ill patients in over 550 hospitals. Her leadership is expected to be instrumental in establishing the Ceribell System as the standard of care in acute settings.
The most recent analyst rating on (CBLL) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.
Ceribell, Inc. faces significant business risks due to potential changes in trade policies and regulations in the United States and other countries. The renegotiation or termination of trade agreements, along with the imposition of tariffs, particularly between the U.S. and China, could disrupt their supply chain and increase production costs. Such changes may adversely impact Ceribell’s product sales, gross margins, and customer demand, while also affecting long-term strategies and financial stability. The company’s efforts to mitigate these risks may not be effective, potentially leading to increased capital and operating costs.
The recent earnings call from Ceribell, Inc. painted a largely positive picture for the company’s future, underscored by robust revenue growth and an optimistic outlook. Despite facing challenges such as increased operating expenses and legal costs, the overall sentiment was upbeat, with the positives significantly outweighing the negatives.
Ceribell, Inc. is a medical technology company specializing in innovative solutions for diagnosing and managing serious neurological conditions, with its flagship product being the Ceribell System, a point-of-care EEG platform. In its second quarter of 2025, Ceribell reported a significant revenue increase of 38% compared to the previous year, reaching $21.2 million. The company also achieved a gross margin of 88% and expanded its active accounts to 584, reflecting strong commercial performance and adoption of its technology. Key financial metrics reveal a rise in product and subscription revenues, with product revenue at $15.9 million and subscription revenue at $5.3 million, both showing substantial year-over-year growth. However, operating expenses increased by 56% due to investments in commercial expansion and public company operations, resulting in a net loss of $13.6 million. Looking ahead, Ceribell has raised its full-year revenue guidance, anticipating growth between 30% and 34%, as it continues to focus on expanding its market presence and advancing its product pipeline.